Deficits in striatal dopamine release in cannabis dependence
Tóm tắt
Từ khóa
Tài liệu tham khảo
Association AP Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th ed. American Psychiatric Publishing: Arlington, VA, USA, pp 2013.
Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ . Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 2014; 136: 158–161.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–328.
Volkow ND, Baler RD, Compton WM, Weiss SR . Adverse health effects of marijuana use. N Engl J Med 2014; 370: 2219–2227.
James A, James C, Thwaites T . The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiatry Res 2013; 214: 181–189.
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932–1936.
Lupica CR, Riegel AC, Hoffman AF . Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004; 143: 227–234.
Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759–766.
Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG . Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001; 107: 173–177.
Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, Stokes PR . Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology 2015; 232: 2723–2729.
Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM . Can recreational doses of THC produce significant dopamine release in the human striatum? NeuroImage 2009; 48: 186–190.
Barkus E, Morrison PD, Vuletic D, Dickson JC, Ell PJ, Pilowsky LS et al. Does intravenous Delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 2011; 25: 1462–1468.
Trifilieff P, Martinez D . Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. Neuropharmacology 2014; 76 Pt B: 498–509.
Volkow ND, Fowler JS, Wang GJ, Baler R, Telang F . Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009; 56 (Suppl 1): 3–8.
Urban NB, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S et al. Dopamine release in chronic cannabis users: a [11c]raclopride positron emission tomography study. Biol Psychiatry 2012; 71: 677–683.
Mizrahi R, Suridjan I, Kenk M, George TP, Wilson A, Houle S et al. Dopamine response to psychosocial stress in chronic cannabis users: a PET study with [11C]-+-PHNO. Neuropsychopharmacology 2013; 38: 673–682.
Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA 2014; 111: E3149–E3156.
Bloomfield MA, Morgan CJ, Egerton A, Kapur S, Curran HV, Howes OD . Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms. Biol Psychiatry 2014; 75: 470–478.
Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K et al. Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology 2014; 39: 1479–1489.
Tziortzi AC, Haber SN, Searle GE, Tsoumpas C, Long CJ, Shotbolt P et al. Connectivity-based functional analysis of dopamine release in the striatum using diffusion-weighted MRI and positron emission tomography. Cereb Cortex 2014; 24: 1165–1177.
Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P et al. Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 2006; 97: 1089–1103.
Dougherty DM, Mathias CW, Dawes MA, Furr RM, Charles NE, Liguori A et al. Impulsivity, attention, memory, and decision-making among adolescent marijuana users. Psychopharmacology 2013; 226: 307–319.
Landau SM, Lal R, O'Neil JP, Baker S, Jagust WJ . Striatal dopamine and working memory. Cereb Cortex 2009; 19: 445–454.
Wilkinson L, Tai YF, Lin CS, Lagnado DA, Brooks DJ, Piccini P et al. Probabilistic classification learning with corrective feedback is associated with in vivo striatal dopamine release in the ventral striatum, while learning without feedback is not. Hum Brain Mapp 2014; 35: 5106–5115.
de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011; 36: 1781–1791.
Kraguljac NV, White DM, Reid MA, Lahti AC . Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013; 70: 1294–1302.
Semple DM, McIntosh AM, Lawrie SM . Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005; 19: 187–194.
Cachope R, Cheer JF . Local control of striatal dopamine release. Front Behav Neurosci 2014; 8: 188.
Gerdeman G, Lovinger DM . CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001; 85: 468–471.
Sneider JT, Mashhoon Y, Silveri MM . A review of magnetic resonance spectroscopy studies in marijuana using adolescents and adults. J Addict Res Ther 2013; (Suppl 4):pii: 010.
Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 51: 849–859, discussion 863-844.
Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J . Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996; 153: 1195–1201.
Sobell LC, Sobell MB . Timeline Followback: A Calendar Method for Assessing Alcohol and Drug Use. Addiction Research Foundation: Toronto, Ontario, Canada, 1996.
Heishman SJ, Singleton EG . Assessment of cannabis craving using the Marijuana Craving Questionnaire. Methods Mol Med 2006; 123: 209–216.
Patton JH, Stanford MS, Barratt ES . Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995; 51: 768–774.
Kay SR, Fiszbein A, Opler LA . The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.
Hollingshead AB . Four factor index of social status. 1975 Working paper available from Department of Sociology, Yale University: New Haven, CT, USA.
Cohen JD, Forman SD, Braver TS, Casey BJ, Servan-Schreiber D, Noll DC . Activation of the prefrontal cortex in a nonspatial working memory task with functional MRI. Hum Brain Mapp 1994; 1: 293–304.
Knowlton BJ, Squire LR, Gluck MA . Probabilistic classification learning in amnesia. Learning Memory 1994; 1: 106–120.
Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 2001; 21: 1034–1057.
Lammertsma AA, Hume SP . Simplified reference tissue model for PET receptor studies. NeuroImage 1996; 4 (3 Pt 1): 153–158.
Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH et al. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users. Drug Alcohol Depend 2013; 128: 52–57.
Sevy S, Smith GS, Ma Y, Dhawan V, Chaly T, Kingsley PB et al. Cerebral glucose metabolism and D2/D3 receptor availability in young adults with cannabis dependence measured with positron emission tomography. Psychopharmacology 2008; 197: 549–556.
Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C et al. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 2012; 17: 642–649.
Sneider JT, Pope HG Jr, Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA . Differences in regional blood volume during a 28- day period of abstinence in chronic cannabis smokers. Eur Neuropsychopharmacol 2008; 18: 612–619.
Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD et al. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 2013; 73: 242–248.
Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004; 161: 1211–1218.
Ceccarini J, De Hert M, Van Winkel R, Peuskens J, Bormans G, Kranaster L et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage 2013; 79: 304–312.
Martin AB, Fernandez-Espejo E, Ferrer B, Gorriti MA, Bilbao A, Navarro M et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008; 33: 1667–1679.
Van Waes V, Beverley JA, Siman H, Tseng KY, Steiner H . CB1 cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation. Front Pharmacol 2012; 3: 21.
Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T et al. Affinity and selectivity of [(1)(1)C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012; 66: 489–500.
Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 2006; 5: 25–43.
Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M et al. Imaging dopamine D-3 receptors in the human brain with positron emission tomography, [C-11]PHNO, and a selective D-3 receptor antagonist. Biol Psychiatry 2010; 68: 392–399.
Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S et al. Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 2012; 32: 127–136.
Rabiner EA, Laruelle M . Imaging the D3 receptor in humans in vivo using [11C](+)-PHNO positron emission tomography (PET). Int J Neuropsychopharmacol 2010; 13: 289–290.
Searle GE, Beaver JD, Tziortzi A, Comley RA, Bani M, Ghibellini G et al. Mathematical modelling of [(1)(1)C]-(+)-PHNO human competition studies. NeuroImage 2013; 68: 119–132.
Rabiner E, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R et al. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)PHNO: studies in non-hman primates and transgenic mice. Synapse 2009; 63: 782–793.
Gallezot JD, Zheng MQ, Lim K, Lin SF, Labaree D, Matuskey D et al. Parametric imaging and test-retest variability of (1)(1)C-(+)-PHNO binding to D(2)/D(3) dopamine receptors in humans on the high-resolution research tomograph PET scanner. J Nucl Med 2014; 55: 960–966.
Bloomfield MA, Morgan CJ, Kapur S, Curran HV, Howes OD . The link between dopamine function and apathy in cannabis users: an [18 F]-DOPA PET imaging study. Psychopharmacology 2014; 231: 2251–2259.
Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 932–940.
SAMHSA Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Center for Behavioral Health Statistics and Quality: Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2014.